ERAAP modulation: A possible novel strategy for cancer immunotherapy?

Oncoimmunology. 2012 Jan 1;1(1):81-82. doi: 10.4161/onci.1.1.17828.

Abstract

Recent findings demonstrate that loss of ERAAP, an endoplasmic reticulum aminopeptidase involved in antigen processing, plays a key role in stimulating anti-tumor innate and adaptive immune responses. We show that MHC class I molecules produced in the absence of ERAAP retain their capability of presenting antigens to CD8+ T cells, but not of inhibiting NK cells.